SCHEMBL4484547

SCHEMBL4484547

COc1ccc2cc(C(=O)O)c(NCc3cccc(N)c3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
HPGDS O60760 1/20 0.44
NOS1 P29475 1/20 0.44
AURKA O14965 2/20 0.44
RPS6KB1 P23443 2/20 0.44
EGFR P00533 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
APEX1 P27695 1/20 0.43
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 1/20 0.41
HIF1A Q16665 1/20 0.41
JAK1 P23458 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500058 0.91 SMN1; SMN2 (0.53) APPSMN1; SMN2HPGDSAURKARPS6KB1
SCHEMBL4489260 0.89 HPGDS (0.55) APPSMN1; SMN2HPGDSEGFRRAB9A
SCHEMBL4482149 0.88 KDM4E (0.47) APPHPGDSNOS1AURKARPS6KB1
SCHEMBL4501469 0.88 APEX1 (0.49) APPSMN1; SMN2HPGDSEGFRMEN1
SCHEMBL4496183 0.88 LMNA (0.46) APPSMN1; SMN2HPGDSAURKARPS6KB1
SCHEMBL4482214 0.86 AURKA (0.49) APPSMN1; SMN2NOS1AURKARPS6KB1
SCHEMBL4487073 0.86 KDM4E (0.53) APPHPGDSEGFRMEN1KMT2A
SCHEMBL4493680 0.85 MITF (0.56) APPAURKARPS6KB1MEN1KMT2A
SCHEMBL4489700 0.84 HIF1A (0.58) SMN1; SMN2AURKARPS6KB1MEN1KMT2A
SCHEMBL4477510 0.83 KDM4E (0.47) SMN1; SMN2HPGDSEGFRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 APP 4801/4885SMN1; SMN2 4328/4885HPGDS 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.